1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62310CA8342D32CD0852575A7006B12E7
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/achieving-public-relations-excellence-post-launch-and-through-patent-expiration?opendocument
18
19opendocument
203.234.210.89
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Public Relations

Achieving Public Relations Excellence Post-Launch and Through Patent Expiration

ID: 5033


Features:

20 Info Graphics

3 Data Graphics

20+ Metrics

20+ Best Practices


Pages/Slides: 41


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Achieving Public Relations Excellence Post-Launch and Through Patent Expiration"

STUDY OVERVIEW

A tried and true marketing tool of the pharmaceutical industry, Public Relations is commonly used in the early part of a product's market life. But Public Relations can play an important role in the dusk of a product's life as well. In the later stage of the product lifecycle, the importance of Public Relations rests in its ability to maintain, extend and transition the product. During these stages, it is important for companies to maintain the initial buzz that surrounded a product at launch, as well as change the mix and objectives of their Public Relations efforts to adapt to the needs of a maturing product. Savvy communications leaders penetrate into core customer groups by building strong ties to social network communities, sponsoring educational seminars for existing and new patient sub-populations and radiating information through articles, websites and alerts.

This research identifies which Public Relations tools and activities most effectively educate and inform consumers after a product has been launched. The study also delivers insights into the most effective Public Relations channels, tactics and calls-to-action for reaching consumers of pharmaceutical products, and includes three case studies of how an effective Public Relations campaign can impact a product’s success in the later phases of its lifecycle.

KEY TOPICS
Benefits of Creating Sponsorships with Patient Groups
Personalizing the Medical Condition through Lifestyle Campaigns
Utilizing Positioning to Enhance Product Appeal
Using Market Research to Leverage Public Relations to Motivate Untreated Patients
Benefits of Focusing Public Relations on Underlying Condition
Utilizing Public Relations to Continue Success through Patent Expiration

KEY METRICS
Rating Effectiveness of Public Relations Tools for Building the Brand, Post-Launch
Rating Effectiveness of Public Relations Tools During Mature Stage of a Product’s Lifecycle
Rating Effectiveness of Public Relations Tools at Patent Expiration

SAMPLE KEY FINDINGS
Public Relations Strategies, Tools & Tactics Can Profitably Extend The Brand During Its Later-Life Stages:
o Sub-Populations: Certain Public Relations tactics prove very useful for targeting new sub-populations that are under-served or newly served by the brand. Social networking communities are effective ways for patients, family members and friends to share information and resources and offer support about a common medical condition.
o Advertorials: Advertorials that integrate human-interest story lines and patient or physician testimonials are a highly effective Public Relations form for the later-stage lifecycle.
o Online Communities: The Internet has fostered rapidly growing online communities of patients and common medical interest groups. Savvy brand teams are extending their Public Relations campaigns to these online communities to win brand loyalty and referrals during a product’s final years in the market.
Public Relations Can Help Build A Bridge from First-Generation Success to Next-Generation Blockbuster:
o Building Bridges: Integrated Public Relations and communication strategies helped AstraZeneca and Eli Lilly build sturdy bridges from Prilosec to Nexium and from Prozac to Cymbalta. This “bridge building” requires good planning and, ideally, should commence at the back end of the first-generation product’s lifecycle.

STUDY METHODOLOGY
Executives from 18 bio-pharmaceutical companies shared their strategies, lessons learned and best practices on Public Relations applied post-launch. Leaders from seven partner companies, including Abbott, Boiron, Genentech, Johnson & Johnson, Merck Serono, Novartis and Novo Nordisk, participated in detailed, qualitative interviews.

KEY DEFINITIONS
For the purposes of this study, the following definitions are used:

PR – Public Relations; the practice of managing the flow of information between an organization and its public

DTCDirect-to-consumer; a form of advertising, typically used in the marketing of pharmaceutical products, directed toward patients as opposed to healthcare professionals.


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device


Companies Profiled:
Abbott; AstraZeneca; AtheroGenics; Boehringer Ingelheim; Boiron; Cubist Pharmaceuticals; Emcure; Farmasa Schwabe; Gebauer Company; Jazz Pharmaceuticals; Johnson & Johnson; Merck Serono; Novartis; Novo Nordisk; Pfizer; Solvay Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.